The estimated Net Worth of Eugene Bauer is at least $282 Тысяча dollars as of 8 August 2017. Eugene Bauer owns over 5,000 units of Kadmon Inc stock worth over $47,500 and over the last 8 years he sold KDMN stock worth over $0. In addition, he makes $234,688 as Independent Director at Kadmon Inc.
Eugene has made over 1 trades of the Kadmon Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of KDMN stock worth $11,800 on 8 August 2017.
The largest trade he's ever made was buying 5,000 units of Kadmon Inc stock on 8 August 2017 worth over $11,800. On average, Eugene trades about 556 units every 0 days since 2016. As of 8 August 2017 he still owns at least 5,000 units of Kadmon Inc stock.
You can see the complete history of Eugene Bauer stock trades at the bottom of the page.
Dr. Eugene Bauer, M.D. serves as Independent Director of the Company. Dr. Bauer co-founded Dermira, a publicly traded specialty biopharmaceutical company acquired by Eli Lilly and Company in 2020. Dr. Bauer served as Chief Medical Officer of Dermira, a wholly owned subsidiary of Lilly, through March 2020. Prior to founding Dermira, Dr. Bauer served as Director, President and Chief Medical Officer of Pelpin, Inc., a publicly traded specialty pharmaceutical company, from 2008 to 2009. Dr. Bauer served as Chief Executive Officer of Neosil, Inc., a specialty pharmaceutical company, from 2004 to 2008, and he co-founded and served as a member of the board of directors at Connetics, a publicly traded specialty pharmaceutical company, from 1990 to 2006. Prior to initiating his career in industry, Dr. Bauer served as Dean of Stanford University School of Medicine from 1995 to 2001 and as Chair of the Department of Dermatology at Stanford University School of Medicine from 1988 to 1995. Dr. Bauer is the Lucy Becker Professor Emeritus at Stanford University School of Medicine, a position he has held since 2002. Dr. Bauer was a U.S. National Institutes of Health (“NIH”)-funded investigator for 25 years and has served on review groups and Councils for the NIH. Dr. Bauer currently serves as a board member for First Wave Technologies. He is member of numerous honorific societies, including the National Academy of Medicine. Dr. Bauer received his B.S. from Northwestern University and his M.D. from Northwestern University Medical School.
As the Independent Director of Kadmon Inc, the total compensation of Eugene Bauer at Kadmon Inc is $234,688. There are 8 executives at Kadmon Inc getting paid more, with Harlan Waksal having the highest compensation of $4,742,770.
Eugene Bauer is 77, he's been the Independent Director of Kadmon Inc since 2010. There are no older and 10 younger executives at Kadmon Inc.
Eugene's mailing address filed with the SEC is C/O KADMON HOLDINGS, INC., 450 E. 29TH STREET, NEW YORK, NY, 10016.
Over the last 8 years, insiders at Kadmon Inc have traded over $7,020,661 worth of Kadmon Inc stock and bought 7,084,916 units worth $54,943,934 . The most active insiders traders include Advisors Llcperceptive Life..., Asset Management Lp Golden ... и Daniel S Third Point Llc Loeb. On average, Kadmon Inc executives and independent directors trade stock every 29 days with the average trade being worth of $1,948,175. The most recent stock trade was executed by Harlan Waksal on 13 March 2020, trading 16,000 units of KDMN stock currently worth $46,880.
Kadmon is a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. Its clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies.
Kadmon Inc executives and other stock owners filed with the SEC include: